We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. I was elated when I got the news about receiving […]
We caught up with the 2023 CANTAB™ Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minhowho. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am deeply grateful to Cambridge Cognition
Kaufman discusses the ways the digital biomarkers are improving Alzheimer’s research by directly tackling some of the unique challenges that researchers face. by Mike HollanOriginally published on PharmExec.com Researching and developing treatments for Alzheimer’s disease comes with unique challenges, due to the nature of the disease. Liam Kaufman, VP of clinical sciences at Cambridge Cognition, spoke
The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality. At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog
Technology for successful decentralised clinical trials Read More »
Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is
Why don’t we trust people’s lived-experience of fatigue? Read More »
A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.
Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.
Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease Read More »
The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments.
There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.
The next generation of treatments for Alzheimer’s Disease in clinical trials Read More »
The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.
Highlights from AAIC 2023 Read More »
Insights Back to resource centre 6 October 2022 Understanding the effect of ashwagandha root extract on stress, sleep and cognition We caught up with Shefali Thanawala from Nutriventia Ltd who told us how CANTAB™ helped them to investigate the effects of Ashwagandha root extract on memory and focus in healthy, stressed adults. About Nutriventia, Ltd.Nutriventia Limited is the dietary supplements
Using a multidisciplinary approach to characterise the neurobiology of addiction Read More »
Insights Back to resource centre 31 May 2023 Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference. Earlier this month we had the pleasure of attending the Schizophrenia International Research Society (SIRS) conference in Toronto, Canada. We were delighted to present our recent findings from our meta-analysis comparing
